ROCKVILLE, Md., April 27 /PRNewswire/ -- Accelovance, a privately held vaccine-focused clinical research company, enthusiastically announced today that it has been named the "Best Contract Research Organization" (CRO) at the 2010 World Vaccine Congress, held in Chantilly, VA last week. This is the second consecutive year Accelovance has received this prestigious honor.
"The past 12 months certainly had its challenges; H1N1, the economy and overall funding in our industry. Such an environment welcomed Accelovance's problem solving and proactive execution for clients of varying size with diverse needs," commented President and CEO, Stephen J. Trevisan.
Accelovance has had an unwavering focus on the vaccine industry; innovatively leveraging insight gained from the ownership of clinical sites, flexible CRO solutions, patient recruitment tactics and clinical call center applications to design and implement dynamic study management. A highlight of the year and testament to Accelovance's ability to optimize efficiencies was the simultaneous management of three time-sensitive adult and pediatric vaccine programs; all of which executed high volume, controlled enrollment within reduced timelines through fewer sites.
"There is a lot of pride in consistently delivering on the commitments we make to our clients every day and we are honored to be the recipient of this award again," commented Lee Barsky, Vice President of CRO Services.
The Vaccine Industry Excellence (ViE) awards were established to generate public recognition of the efforts, accomplishments, and positive contributions of organizations and individuals in the global vaccine industry. The "Best CRO" Award is designed to highlight the importance of contract research services within the vaccine industry; the winner is selected by a panel of international judges.
Headquartered in Rockville, Maryland, Accelovance is a privately held company that has developed a unique operational approach for delivering quality, on time, and cost effective clinical studies. Accelovance offers wholly-owned, research-dedicated clinical sites to Sponsors and CROs that bring greater control, predictability, and quality assurance to vaccine programs. Additionally, the Company tailors its offering of full CRO, Clinical Sites, Patient Recruitment, and Call Center to present a clinical solution that meets a Sponsor's needs. Accelovance has a 100% owned subsidiary providing CRO services in China. These capabilities can assist clients with global development programs or product registration in China, the fastest growing pharmaceutical market in the world.
For more information, visit the company's website at http://www.accelovance.com.